Veradermics, Inc Basic Shares Outstanding (Weighted Average)
Veradermics, Inc (MANE) reported Basic Shares Outstanding (Weighted Average) of 40.44 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfSharesOutstandingBasic · last filed 2026-08-11
- Veradermics, Inc weighted average number of shares outstanding, basic for the quarter ending 2026-06-30 was 40.44M shares, a 5330.30% increase year-over-year.
- Veradermics, Inc weighted average number of shares outstanding, basic for the quarter ending 2026-03-31 was 22.70M shares, a 2980.89% increase year-over-year.
- Veradermics, Inc weighted average number of shares outstanding, basic for the quarter ending 2025-06-30 was 744.64K shares.
- Veradermics, Inc weighted average number of shares outstanding, basic for the quarter ending 2025-03-31 was 736.93K shares.
- Veradermics, Inc weighted average number of shares outstanding, basic for fiscal 2025 was 744.99K shares, a 1.09% increase from fiscal 2024.
- Veradermics, Inc weighted average number of shares outstanding, basic for fiscal 2024 was 736.93K shares.
| Period end | Weighted Average Number of Shares Outstanding, Basic 3 month | Weighted Average Number of Shares Outstanding, Basic 6 month | Weighted Average Number of Shares Outstanding, Basic 12 month |
|---|---|---|---|
| 2026-06-30 | 40.44M shares 10-Q · filed 2026-08-11 | 31.62M shares 10-Q · filed 2026-08-11 | |
| 2026-03-31 | 22.70M shares 10-Q · filed 2026-05-12 | ||
| 2025-12-31 | 744.99K shares 10-K · filed 2026-03-30 | ||
| 2025-06-30 | 744.64K shares 10-Q · filed 2026-08-11 | 740.81K shares 10-Q · filed 2026-08-11 | |
| 2025-03-31 | 736.93K shares 10-Q · filed 2026-05-12 | ||
| 2024-12-31 | 736.93K shares 10-K · filed 2026-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |